Disease · MONDO_0008575

nicotine dependence

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. nicotine dependence. Diseases, record MONDO_0008575. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0008575

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: nicotine dependence; Open Targets
Open Targets ID: MONDO_0008575; Open Targets
Other names: Cigarette Smoking, Dependence, Nicotine, Dependence, Tobacco, Disorder, Nicotine Use, Disorder, Tobacco Use, NICOTINE USE DIS, Nicotine Use Disorder, Nicotine Use Disorders, Smoking, Cigarette, Smoking, Tobacco, Smokings, Tobacco, TOBACCO USE DIS, Tobacco Dependence, Tobacco Dependences, Tobacco Smoking, Tobacco Smokings, Tobacco Use Disorder, Tobacco Use Disorders, Use Disorder, Nicotine, nicotine addiction, smoking; Open Targets
Disease Ontology: DOID:0050742; Disease Ontology
MeSH: D014029; MeSH
NCI Thesaurus: C54203; NCI Thesaurus
Highest stage of its drugs: Approval, for 4 of its 93 drugs, from ATC and TTD; Open Targets

Drugs93

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
NICOTINE	CHEMBL3	Small molecule	Approval	ATC and TTD	254	250	247	Drugs and targets
(+/-)NICOTINE	CHEMBL440464	Small molecule	Approval	TTD	238	235	232	Drugs and targets
VARENICLINE	CHEMBL1076903	Small molecule	Approval	ATC	129	128	128	Drugs and targets
CYTISINICLINE	CHEMBL497939	Small molecule	Approval	ATC	20	18	18	Drugs and targets
BUPROPION	CHEMBL894	Small molecule	Phase 3	ClinicalTrials.gov	52	52	52	Drugs and targets
NICOTINE POLACRILEX	CHEMBL1201536		Phase 3	ClinicalTrials.gov	7	7	7	Drugs and targets
NALTREXONE	CHEMBL19019	Small molecule	Phase 3	ClinicalTrials.gov	6	6	6	Drugs and targets
ACETYLCYSTEINE	CHEMBL600	Small molecule	Phase 3	ClinicalTrials.gov	5	5	3	Drugs and targets
METHYLPHENIDATE	CHEMBL796	Small molecule	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets
TOPIRAMATE	CHEMBL220492	Small molecule	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets

1 to 10 of 93

See all 93 drugs

Targets126

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
SLC6A2	Monoamine transporter	7	Monoamine transporter inhibitor; Norepinephrine transporter inhibitor; Norepinephrine transporter releasing agent	Phase 3	https://conductscience.org/library/genes/6530	Drugs and targets
CHRNA4	Neuronal acetylcholine receptor; alpha4/beta2	6	Neuronal acetylcholine receptor; alpha4/beta2 agonist; Neuronal acetylcholine receptor; alpha4/beta2 partial agonist	Approval	https://conductscience.org/library/genes/1137	Drugs and targets
CHRNB2	Neuronal acetylcholine receptor; alpha4/beta2	6	Neuronal acetylcholine receptor; alpha4/beta2 agonist; Neuronal acetylcholine receptor; alpha4/beta2 partial agonist	Approval	https://conductscience.org/library/genes/1141	Drugs and targets
GRIN2A	Glutamate [NMDA] receptor	6	Glutamate [NMDA] receptor antagonist; Glutamate [NMDA] receptor negative allosteric modulator; Glutamate [NMDA] receptor subunit epsilon 1 antagonist	Phase 2	https://conductscience.org/library/genes/2903	Drugs and targets
SLC6A3	Monoamine transporter	6	Dopamine transporter inhibitor; Dopamine transporter releasing agent; Monoamine transporter inhibitor	Phase 3	https://conductscience.org/library/genes/6531	Drugs and targets
GRIN1	Glutamate [NMDA] receptor	5	Glutamate [NMDA] receptor antagonist; Glutamate [NMDA] receptor negative allosteric modulator	Phase 2	https://conductscience.org/library/genes/2902	Drugs and targets
GRIN2B	Glutamate [NMDA] receptor	5	Glutamate [NMDA] receptor antagonist; Glutamate [NMDA] receptor negative allosteric modulator	Phase 2	https://conductscience.org/library/genes/2904	Drugs and targets
GRIN2C	Glutamate [NMDA] receptor	5	Glutamate [NMDA] receptor antagonist; Glutamate [NMDA] receptor negative allosteric modulator	Phase 2	https://conductscience.org/library/genes/2905	Drugs and targets
GRIN2D	Glutamate [NMDA] receptor	5	Glutamate [NMDA] receptor antagonist; Glutamate [NMDA] receptor negative allosteric modulator	Phase 2	https://conductscience.org/library/genes/2906	Drugs and targets
GRIN3A	Glutamate [NMDA] receptor	5	Glutamate [NMDA] receptor antagonist; Glutamate [NMDA] receptor negative allosteric modulator	Phase 2	https://conductscience.org/library/genes/116443	Drugs and targets

1 to 10 of 126

See all 126 targets

Trials468

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 4 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00356993	Phase I Study: Stop Smoking Therapy for Ontario Patients (STOP)	Not applicable	6,009	2019-05-02	Smoking	(+/-)NICOTINE, NICOTINE	Its record names the disease	ClinicalTrials.gov
NCT01502306	A Randomized Trial of Medi-Cal Beneficiaries Calling the California Smokers' Helpline	Phase 3	3,816	2019-10-01	Smoking Cessation	(+/-)NICOTINE, NICOTINE	Its record names the disease	ClinicalTrials.gov
NCT01736085	Providing Free Nicotine Patches to Quitline Smokers	Phase 3	3,706	2020-02-19	Smoking Cessation	(+/-)NICOTINE, NICOTINE	Its record names the disease	ClinicalTrials.gov
NCT00775944	Trial Comparing Different Methods of Support With Stopping Smoking (PORTSSS/Stop Together Trial)	Phase 4	2,591	2012-10-26	Tobacco Smoking	(+/-)NICOTINE, NICOTINE	Its record names the disease	ClinicalTrials.gov
NCT00534404	A Randomized Trial of Internet Access to Nicotine Patches	Not applicable	2,485	2015-02-03	Smoking Cessation, Tobacco Use Disorder	(+/-)NICOTINE, NICOTINE	Its record names the disease	ClinicalTrials.gov
NCT00352781	Stop Smoking Therapy for Ontario Patients	Not applicable	1,767	2012-04-17	Smoking	(+/-)NICOTINE, NICOTINE	Its record names the disease	ClinicalTrials.gov
NCT03538938	Improving Quitline Support Study	Phase 4	1,316	2024-07-12	Tobacco Use Cessation	NICOTINE	Its record names the disease	ClinicalTrials.gov
NCT00632411	Evaluating a Telephone-Based Smoking Cessation Program Among People in the Military (The AFIII Study)	Not applicable	1,298	2017-05-24	Smoking, Smoking Cessation	(+/-)NICOTINE, NICOTINE	Its record names the disease	ClinicalTrials.gov
NCT01314001	Pharmacogenetics of Nicotine Addiction Treatment	Phase 3	1,246	2016-03-03	Nicotine Addiction	(+/-)NICOTINE, NICOTINE, VARENICLINE	Its record names the disease	ClinicalTrials.gov
NCT02896400	Optimizing Tobacco Dependence Treatment in the Emergency Department	Phase 3	1,056	2020-11-16	Tobacco Use Disorder	(+/-)NICOTINE, NICOTINE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 468

See all 468 trials

Comparisons in its trials315

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Proactive Group vs Reactive Group: serious adverse events	16 of 649	6 of 649	1,298	NCT00632411	Trial comparisons
Proactive Group vs Reactive Group: Continuous Abstinence	173 of 521	136 of 529	1,050	NCT00632411	Trial comparisons
Intervention vs Control: Number of Participants With Self-reported Tobacco Abstinence in Past 7 Days	95 of 482	79 of 352	834	NCT03717051	Trial comparisons
Intervention vs Control: Number of Participants With Self-reported Use of NRT in Past Week/Month	92 of 482	86 of 352	834	NCT03717051	Trial comparisons
Intervention vs Control: Number of Participants With Self-reported Quit Attempt	214 of 482	153 of 352	834	NCT03717051	Trial comparisons
Intervention vs Control: Number of Participants With Self-reported Tobacco Abstinence in Past 7 Days	104 of 482	92 of 352	834	NCT03717051	Trial comparisons
Intervention vs Control: Number of Participants Who Enroll in Any Smoking Cessation Service in Hong Kong	156 of 482	158 of 352	834	NCT03717051	Trial comparisons
Intervention vs Control: Number of Participants With Self-reported Quit Attempt	300 of 482	243 of 352	834	NCT03717051	Trial comparisons
Intervention vs Control: Number of Participants Who Enroll in Any Smoking Cessation Service in Hong Kong	247 of 482	213 of 352	834	NCT03717051	Trial comparisons
Intervention vs Control: Biochemically Validated Abstinence at 6-month Follow-up	22 of 482	10 of 352	834	NCT03717051	Trial comparisons

1 to 10 of 315

See all 315 comparisons in its trials

Papers from its trials352

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
39477130	RESULT	1	PubMed
37889541	RESULT	1	PubMed
33853658	RESULT	1	PubMed
32578165	RESULT	1	PubMed
32559759	RESULT	1	PubMed
32151567	RESULT	1	PubMed
31725711	RESULT	1	PubMed
31241286	RESULT	1	PubMed
30932386	RESULT	1	PubMed
30797382	RESULT	1	PubMed

1 to 10 of 352

See all 352 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0008575

GET https://conductscience.org/api/diseases/v1/MONDO_0008575/drugs?page=2

API reference For AI assistants